Application of Reg1A in preparation of kit for clinical diagnosis and grading and staging evaluation of pancreatic diseases

By using the Reg1A biomarker to detect pancreatic diseases, a kit for pancreatic diseases was prepared, which solved the problems of insufficient sensitivity and specificity in the diagnosis and staging assessment of existing technologies, and achieved highly accurate diagnosis and staging assessment of pancreatic diseases.

CN118962148APending Publication Date: 2024-11-15THE FIRST AFFILIATED HOSPITAL OF NAVAL MEDICAL UNIVERSITY OF CHINESE PEOPLES LIBERATION ARMY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411041555.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing technologies have insufficient sensitivity and specificity in the early diagnosis and staging assessment of pancreatic diseases. Imaging examinations are expensive and complex to perform, while serum biomarkers such as CEA, CA19-9 and CA125 have low diagnostic specificity and sensitivity, making it difficult to achieve early diagnosis.

Method used

Using Reg1A as a biomarker, serum Reg1A levels were detected by enzyme-linked immunosorbent assay (ELISA) or Western blotting to prepare a kit for the clinical diagnosis and staging assessment of pancreatic diseases. Different concentration thresholds were set to determine the disease type and severity.

Benefits of technology

It improves the accuracy of diagnosis and staging assessment of pancreatic diseases, with high specificity and sensitivity, which helps to improve patient prognosis and treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004972515220000061
    Figure BDA0004972515220000061
  • Figure BDA0004972515220000071
    Figure BDA0004972515220000071
  • Figure BDA0004972515220000081
    Figure BDA0004972515220000081
Patent Text Reader

Abstract

The invention provides an application of a human regenerative pancreas islet derived protein 1 alpha (Reg1A) in preparation of a kit for clinical diagnosis and grading and staging evaluation of pancreatic diseases. It is verified that Reg1A can be used for rapid clinical diagnosis and grading and staging evaluation of pancreatic diseases, accuracy is high, sensitivity and specificity are good, patient prognosis is improved, and the treatment effect is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of biomedicine and disease diagnosis, and in particular to the use of human regenerating islet-derived protein 1α (Reg1A) in preparing a kit for clinical diagnosis and grading and staging evaluation of pancreatic diseases. Background Art

[0002] Pancreatic diseases, mainly including acute pancreatitis, chronic pancreatitis and pancreatic cancer, are a type of disease that seriously affects the health of patients. Acute pancreatitis is a common acute abdomen with great differences in severity and complications, ranging from mild self-limiting diseases to severe pancreatic necrosis, multiple organ failure, and even life-threatening. Chronic pancreatitis is a disease characterized by persistent and progressive inflammation of the pancreas, manifested as pancreatic parenchymal fibrosis and loss of endocrine and endocrine functions. The course of the disease is protracted and the patient's quality of life is reduced. Pancreatic cancer is one of the most lethal cancers worldwide. Its early diagnosis is extremely difficult. Patients are mostly diagnosed in the advanced stage with a poor prognosis. Therefore, early diagnosis and accurate staging of pancreatic disease are crucial to improving patient prognosis and enhancing treatment effectiveness.

[0003] The diagnosis of pancreatic diseases currently relies mainly on imaging examinations and serum marker detection. Commonly used imaging examinations include ultrasound, CT, MRI, and endoscopic ultrasound, which play an important role in diagnosing pancreatic tumors and assessing the extent and severity of the disease. However, imaging examinations have certain limitations, especially in the early stages of chronic pancreatitis and pancreatic cancer, when pancreatic changes are mild or the tumor is hidden, the sensitivity and specificity of imaging examinations are limited. In addition, imaging examinations are expensive and complicated to operate, making them unsuitable for large-scale screening.

[0004] Serum marker detection is a simple, rapid and non-invasive diagnostic method, and has important applications in the early screening and monitoring of pancreatic diseases. At present, the commonly used serum markers for pancreatic cancer in clinical practice include carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125). However, the specificity and sensitivity of these markers for diagnosing pancreatic cancer are low, especially CA19-9, which can also be elevated in chronic pancreatitis and other benign diseases, which can easily lead to false positive results. In addition, for patients with early pancreatic cancer, the sensitivity of these markers is poor, making it difficult to achieve early diagnosis. There is currently a lack of early diagnostic markers for chronic pancreatitis.

[0005] Reg1A is a secretory protein highly expressed in the pancreas, encoded by the regI gene. It consists of 144 amino acids and has a relative molecular weight of ~16kD. Studies have shown that Reg1A plays an important role in pancreatic tissue damage, regeneration, and carcinogenesis. Reg1A levels are significantly increased in the serum and urine of patients with pancreatic cancer and pancreatitis. Therefore, Reg1A is expected to become a new pancreatic disease marker with high specificity and sensitivity. Summary of the invention

[0006] In order to overcome the defects in the prior art, the present invention provides the use of Reg1A in preparing a kit for clinical diagnosis and grading and staging evaluation of pancreatic diseases.

[0007] To achieve the above object, the present invention adopts the following technical solution:

[0008] The present invention provides the use of a reagent for detecting Reg1A in preparing a kit for clinical diagnosis and / or grading and staging evaluation of pancreatic diseases; the kit comprises the reagent for detecting Reg1A.

[0009] In some embodiments of the present invention, the reagent for detecting Reg1A is a reagent for detecting the content of Reg1A in the serum of a subject.

[0010] In some embodiments of the present invention, the pancreatic disease includes one or more of acute pancreatitis, chronic pancreatitis and pancreatic cancer.

[0011] In some specific embodiments of the present invention, when the kit is used to diagnose acute pancreatitis, when the concentration of Reg1A is greater than 354.78 ng / ml, the subject is determined to be a patient with acute pancreatitis; when the kit is used to diagnose chronic pancreatitis, when the concentration of Reg1A is greater than 353.28 ng / ml, the subject is determined to be a patient with chronic pancreatitis; and / or, when the kit is used to diagnose pancreatic cancer, when the concentration of Reg1A is greater than 265.58 ng / ml, the subject is determined to be a patient with pancreatic cancer.

[0012] In some specific embodiments of the present invention, the acute pancreatitis is divided into mild, moderate and severe; when the kit is used for the grading and staging evaluation of acute pancreatitis, when the concentration of Reg1A is greater than 154.70 ng / ml, the subject is determined to be a patient with severe acute pancreatitis, otherwise the subject is a patient with mild to moderate acute pancreatitis.

[0013] In some specific embodiments of the present invention, the chronic pancreatitis is divided into stage 0, stage 1, stage 2, stage 3 and stage 4; when the kit is used for the grading and staging evaluation of chronic pancreatitis, when the concentration of Reg1A is greater than 478.76 ng / ml, the subject is determined to be a patient with stage 3-4 chronic pancreatitis, otherwise the subject is a patient with stage 0, stage 1 or stage 2 chronic pancreatitis.

[0014] In some embodiments of the present invention, the reagent for detecting Reg1A is a reagent for detecting the content of Reg1A in serum based on enzyme-linked immunosorbent assay or Western Blot technology.

[0015] In some specific embodiments of the present invention, the reagent for detecting Reg1A is a reagent for detecting the content of Reg1A in serum based on enzyme-linked immunosorbent assay.

[0016] In some specific embodiments of the present invention, the reagents for detecting Reg1A include a microplate coated with a Reg1A monoclonal antibody, a calibrator, a quality control product, an enzyme-labeled Reg1A monoclonal antibody, a color developer, a stop solution, a washing buffer and a dilution buffer.

[0017] In some specific embodiments of the present invention, the enzyme is horseradish peroxidase HRP, and the color developing agent is TMB substrate solution.

[0018] The present invention adopts the above technical solution, and has the following technical effects compared with the prior art:

[0019] The present invention verifies that human regenerative islet-derived protein 1α (Reg1A) can be used for rapid clinical diagnosis and grading and staging evaluation of pancreatic diseases with high accuracy, which is beneficial to improving patient prognosis and enhancing treatment effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Part A shows serum REG1A levels in healthy controls and patients with acute pancreatitis; Figure 1 Part B shows the performance characteristics of serum REG1A as a biomarker for acute pancreatitis through AUC. When the critical value of serum REG1A is greater than 354.78 ng / ml, it shows the best performance in diagnosing acute pancreatitis.

[0021] Figure 2 Part A shows serum REG1A levels in healthy controls and patients with chronic pancreatitis; Figure 2 Part B shows the performance characteristics of serum REG1A as a biomarker for pancreatic diseases through AUC. When the critical value of serum REG1A is greater than 353.28 ng / ml, it shows the best performance in diagnosing chronic pancreatitis.

[0022] Figure 3 Part A shows serum REG1A levels in healthy controls and pancreatic cancer patients; Figure 3 Part B shows the performance characteristics of serum REG1A as a biomarker for pancreatic diseases through AUC. When the critical value of serum REG1A is greater than 265.58 ng / ml, it shows the best performance in diagnosing pancreatic cancer.

[0023] Figure 4 Part A shows the serum REG1A levels in the acute pancreatitis subgroup of patients; Figure 4 Part B shows the performance characteristics of serum REG1A as a biomarker for the severity of acute pancreatitis through AUC. When the critical value of serum REG1A is greater than 154.70 ng / ml, it shows the best performance in diagnosing severe acute pancreatitis.

[0024] Figure 5 Part A shows the serum REG1A levels in patients with different stages of chronic pancreatitis; Figure 5 Part B shows the performance characteristics of serum REG1A as a biomarker for chronic pancreatitis with pancreatic insufficiency through AUC. When the critical value of serum REG1A is greater than 478.76 ng / ml, it is optimal for diagnosing chronic pancreatitis with complete pancreatic insufficiency. DETAILED DESCRIPTION

[0025] The present invention is described in detail and specifically below through specific embodiments and drawings to provide a better understanding of the present invention, but the following embodiments do not limit the scope of the present invention.

[0026] The methods in the examples are conventional methods unless otherwise specified, and the reagents used are conventional commercial reagents or reagents prepared according to conventional methods unless otherwise specified.

[0027] 1. The regeneration islet-derived protein 1α (Reg1A) detection kit used in the following examples (Changning TM , Shenzhen Shengboer Life Science Co., Ltd.) consists of: a microplate coated with mouse anti-Reg1A monoclonal antibody, Reg1A recombinant protein calibrators and quality control products, HRP-labeled mouse anti-Reg1A monoclonal antibody, TMB substrate solution A / B (3,3',5,5'-tetramethylbenzidine, peroxide), stop solution (0.2 M sulfuric acid), washing buffer, and dilution buffer.

[0028] 2. Sample requirements: Collect serum samples from healthy controls and patients with pancreatic diseases (including acute pancreatitis, chronic pancreatitis and pancreatic cancer).

[0029] 3. Steps for detecting Reg1A: (according to product instructions)

[0030] a. Reagent preparation: All reagents are equilibrated to room temperature for at least 30 minutes, and sample dilution solution and working wash solution are prepared.

[0031] b. Sample processing: Serum samples were diluted at a ratio of 1:200.

[0032] c. Operation steps:

[0033] (1) Sample addition: Add the diluted sample, calibrator, and quality control in sequence, 50 μl / well each. Then add 100 μl of detection antibody to the wells containing the calibrator / quality control and sample, mix well, cover with sealing film, and incubate at 37°C for 90 min.

[0034] (2) Washing the plate: discard the liquid in the wells, wash each well with at least 350 μl of washing solution, soak for 10-30 seconds, aspirate or pour out all the washing solution, repeat 3 times, and after the last wash, pat dry the residual liquid in the ELISA wells with absorbent paper / clean gauze.

[0035] (3) Color development: Take TMB substrates A and B, mix them in a 1:1 ratio, add 150 μl / well to the reaction well, cover with sealing film, and incubate at 37°C in the dark for 15 min.

[0036] (4) Termination: Add 50 μl of stop solution into the reaction well to terminate the reaction and mix well.

[0037] (5) Detection: Use an ELISA reader to measure the OD value of each well at a primary wavelength of 450 nm and a secondary wavelength of 620 / 630 nm. The reading should be taken within 10 minutes after termination.

[0038] 4. Data analysis: Draw a logistic curve fitting (four parameters) based on the absorbance value of the calibrator and the corresponding concentration. Calculate the concentration of Reg1A in the sample through the standard curve based on the absorbance value of the sample. If the sample to be tested exceeds the detection range (i.e. the OD value of the sample is higher than the OD value of the calibrator 6, or exceeds the detection range of the microplate reader), increase the dilution multiple and repeat the test.

[0039] 5. Statistical Analysis

[0040] SPSS software (IBM Corp. 19.0) was used for statistical analysis. Continuous variables were expressed as mean ± standard deviation (SD) or median with interquartile range (IQR). One-way analysis of variance or Kruskal-Wallis test was used to compare continuous variables in multiple groups according to data distribution. Chi-square test was used for analysis of categorical variables. Spearman correlation coefficient was used to analyze the correlation between REG1A level and clinical parameters. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated to quantify the strength of association. Receiver Operating Characteristic Curve (ROC) was used to analyze the diagnostic efficacy of REG1A. R 4.3.1 version was used for ROC curve analysis. Area under the curve (AUC), sensitivity and specificity of the optimal cut-off point were obtained. p value < 0.05 was considered statistically significant.

[0041] Example 1

[0042] 1. Sample preparation: Serum was collected from the First Affiliated Hospital of Naval Medical University.

[0043] 2. Testing steps: Follow the above testing steps.

[0044] 3. Result analysis:

[0045] 1) Baseline information:

[0046] A total of 314 participants were included in this study and divided into four groups: healthy controls (n = 24), patients with acute pancreatitis (AP) (n = 131), patients with chronic pancreatitis (n = 110), and patients with pancreatic cancer (n =

[0047] 49). The demographic and clinical characteristics of each group are shown in Table 1. There were 215 males and 103 females in the study, with a median age of 49 years (range, 12-88 years). A total of 107 patients with pancreatic disease had diabetes.

[0048] Table 1. Clinical baseline information of participants

[0049]

[0050] 2) Diagnosis of acute pancreatitis:

[0051] Compared with healthy controls, serum REG1A levels were significantly increased in patients with acute pancreatitis (p<0.005) ( Figure 1Part A). In the ROC curve evaluation method, when the area under the ROC curve AUC is greater than 0.5, the closer it is to 1, the better the diagnostic effect. AUC has lower accuracy when it is 0.5-0.7, has certain accuracy when it is 0.7-0.9, and has higher accuracy when it is above 0.9. The AUC of REG1A alone for diagnosing acute pancreatitis is 0.9237, which has high accuracy (95% CI: 0.8792-0.9681, cutoff value>354.78ng / ml, sensitivity: 87.5%, specificity: 85.5%) ( Figure 1 Part B of the

[0052] 3) Diagnosis of chronic pancreatitis:

[0053] Compared with the healthy control group, the serum REG1A level in patients with chronic pancreatitis was significantly increased (p<0.005) ( Figure 2 The AUC of REG1A alone for diagnosing chronic pancreatitis was 0.9182, with high accuracy (95% CI: 0.8668-0.9695, cutoff value>353.28ng / ml, sensitivity: 87.5%, specificity: 87.3%) ( Figure 2 Part B of the

[0054] 4) Diagnosis of pancreatic cancer:

[0055] Compared with the healthy control group, the serum REG1A level in pancreatic cancer patients was significantly increased (p<0.005), which had a certain diagnostic value (AUC=0.8512, 95% CI:0.7613-0.9411, cutoff value>265.58ng / ml, sensitivity: 70.8%, specificity: 91.8%) ( Figure 3 ).

[0056] 5) Differentiation value of severe acute pancreatitis:

[0057] The 131 patients with acute pancreatitis included in this study were divided into 59 mild cases, 40 moderate cases, and 32 severe cases according to the classification criteria of the "Guidelines for the Diagnosis and Treatment of Acute Pancreatitis in China (2021)" (Table 2). The age, gender and other parameters of patients in the acute pancreatitis subgroups are shown in Table 3. The median REG1A level in the mild group was 95.67 ng / ml, in the moderate group was 93.19 ng / ml, and in the severe group was 417.24 ng / ml. The REG1A expression level in patients with severe acute pancreatitis was significantly higher than that in patients with mild and moderate acute pancreatitis (p=0.0027 and p=0.0391), while there was no difference between the mild and moderate groups (p=0.7237). The AUC of REG1A alone for diagnosing severe acute pancreatitis was 0.6875 (95% CI: 0.5798-0.7952, cutoff value>154.70 ng / ml, sensitivity: 66.7%, specificity: 68.8%) ( Figure 4 ).

[0058] Table 2. Classification and diagnosis of acute pancreatitis in China

[0059]

[0060] Table 3. Clinical baseline information of patients with acute pancreatitis

[0061]

[0062] 6) Differentiation value of chronic pancreatitis with III-IV pancreatic insufficiency:

[0063] This study included 110 patients with chronic pancreatitis. According to the Guidelines for the Diagnosis and Treatment of Chronic Pancreatitis (2018, Guangzhou) (Table 4), the disease course and clinical phenotype were staged: 8 cases in stage 0 (subclinical stage), 36 cases in stage 1 (no pancreatic insufficiency), 35 cases in stage 2 (partial pancreatic insufficiency), 22 cases in stage 3 (complete pancreatic insufficiency), and 9 cases in stage 4 (painless end stage). The age, gender and other clinical parameters of patients with chronic pancreatitis staging are shown in Table 5.

[0064] Table 4. Clinical stages of chronic pancreatitis

[0065] Clinical staging Clinical characteristics Stage 0 (subclinical stage) Asymptomatic Stage 1 (no pancreatic insufficiency) Abdominal pain or acute pancreatitis Stage 2 (partial pancreatic insufficiency) Pancreatic endocrine or exocrine insufficiency Stage 3 (complete pancreatic insufficiency) Pancreatic endocrine insufficiency Stage 4 (Painless terminal stage) Pancreatic endocrine insufficiency without pain

[0066] Table 5. Clinical baseline information of patients with chronic pancreatitis

[0067]

[0068] Serum REG1A levels were significantly positively correlated with chronic pancreatitis stages (r = 0.432, p = 0.008). We further divided chronic pancreatitis stages into three groups according to the degree of pancreatic insufficiency: stage 0-1 (no pancreatic insufficiency), stage 2 (partial pancreatic insufficiency) and stage 3-4 (complete pancreatic insufficiency). Serum REG1A levels were higher in stage 3-4 compared with stage 0-1 (p = 0.0216) ( Figure 5 Part A). The AUC of REG1A alone for diagnosing chronic pancreatitis with pancreatic insufficiency (stage 3-4) was 0.6977 (95% CI: 0.5957-0.6977, cutoff value>478.76ng / ml, sensitivity: 54.5%, specificity: 83.3%) ( Figure 5 Part B of the

[0069] The specific embodiments of the present invention are described in detail above, but they are only examples, and the present invention is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modification and substitution of the present invention are also within the scope of the present invention. Therefore, the equalization and modification made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.

Claims

1. Use of a reagent for detecting Reg1A in preparing a kit for clinical diagnosis and / or grading and staging evaluation of pancreatic diseases; the kit comprises the reagent for detecting Reg1A.

2. The use according to claim 1, It is characterized in that The reagent for detecting Reg1A is a reagent for detecting the content of Reg1A in the serum of a subject.

3. The use according to claim 2, It is characterized in that The pancreatic disease includes one or more of acute pancreatitis, chronic pancreatitis and pancreatic cancer.

4. The use according to claim 3, It is characterized in that When the kit is used to diagnose acute pancreatitis, when the concentration of Reg1A is greater than 354.78 ng / ml, the subject is determined to be a patient with acute pancreatitis; when the kit is used to diagnose chronic pancreatitis, when the concentration of Reg1A is greater than 353.28 ng / ml, the subject is determined to be a patient with chronic pancreatitis; and / or, when the kit is used to diagnose pancreatic cancer, when the concentration of Reg1A is greater than 265.58 ng / ml, the subject is determined to be a patient with pancreatic cancer.

5. The use according to claim 3, It is characterized in that The acute pancreatitis is divided into mild, moderate and severe cases; when the kit is used for grading and staging assessment of acute pancreatitis, when the concentration of Reg1A is greater than 154.70 ng / ml, the subject is judged to be a patient with severe acute pancreatitis, otherwise the subject is a patient with mild to moderate acute pancreatitis.

6. The use according to claim 3, It is characterized in that The chronic pancreatitis is divided into stage 0, stage 1, stage 2, stage 3 and stage 4; when the kit is used for the grading and staging assessment of chronic pancreatitis, when the concentration of Reg1A is greater than 478.76 ng / ml, the subject is determined to be a patient with stage 3-4 chronic pancreatitis, otherwise the subject is a patient with stage 0, stage 1 or stage 2 chronic pancreatitis.

7. The use according to claim 2, It is characterized in that The reagent for detecting Reg1A is a reagent for detecting the content of Reg1A in serum based on enzyme-linked immunosorbent assay or Western Blot technology.

8. The use according to claim 7, It is characterized in that The reagent for detecting Reg1A is a reagent for detecting the content of Reg1A in serum based on enzyme-linked immunosorbent assay.

9. The use according to claim 8, It is characterized in that The reagents for detecting Reg1A include a microplate coated with a Reg1A monoclonal antibody, a calibrator, a quality control product, an enzyme-labeled Reg1A monoclonal antibody, a color developer, a stop solution, a washing buffer solution and a dilution buffer solution.

10. The use according to claim 9, It is characterized in that The enzyme is horseradish peroxidase HRP, and the color developing agent is TMB substrate solution.